tirzepatide booster Postmenopausal women on the GLP-1 medication (Zepbound) for obesity lost more weight if they were also using menopause hormone therapy, a retrospective cohort study indicated. https://www.medpagetoday.com/endocrinology/menopause/119594 Tirzepatide Weight Loss Injections •

Reducing visceral adiposity has been shown to improve insulin sensitivity, lipid profiles, and inflammatory markers, making it a critical therapeutic target in metabolic disease management

Both can contribute to allodynia in semaglutide users, and understanding them helps explain why the condition sometimes resolves on its own and sometimes requires intervention

Turek FW (1996)

7 Conclusion and future directions Future research should focus on translating preclinical findings to human applications, particularly through chronobiological studies of hormonal-taste interactions and advanced computational modeling of individual taste-metabolism relationships